DOCSLIB.ORG

Lab Code Test Name Cpt4 Code

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

LAB CODE TEST NAME CPT4 CODE LRH U3METH 3-METHYLGLUTACONIC, URINE LRH 5HIAA 5-HIAA, PLASMA LRH U5HIA24 5-HYDROXYINDOLEACETIC ACID 24HR URINE LRH APHAG A. PHAGOCYTOPHILUM PCR LRH A1CGMK A1c w/GLYCOMARK(R) REFLEX LRH ABG ABG 82803 Container:Sodium or Lithium heparin syringe or Capillary collection device Temperature:Ambient LRH ABGHGB ABG WITH HGB STUDIES 82803 Container:Sodium or Lithium heparin syringe Temperature:Room temperature LRH ACET ACETAMINOPHEN 80307 Container:Green-top (heparin) tube or Red-Top Tube Temperature:Ambient, Refrigerated, or Frozen LRH ACHRB ACETYLCHOLINE RECEPTOR BINDING AUTOABS LRH ACHRBL ACETYLCHOLINE RECEPTOR BLOCKING AUTOABS LRH ACHRM AChR MODULATING ABS, SERUM LRH ADAPER ADA, PERITONEAL LRH HUMIRA ADALIMUMAB and AB LRH ADENOAG ADENO/ROTO VIRUS AG DETECTION LRH ADAPL ADENOSINE DEAMINASE,PLEURAL FL LRH ADENOAB ADENOVIRUS ANTIBODY LRH VASO ADH (VASOPRESSIN) LRH AD21OH ADRENAL 21-HYDROXYLASE AUTOABS LRH ADRENAB ADRENAL TOTAL AUTOABS LRH ACTH ADRENOCORTICOTROPIC HORMONE LRH AERID AEROBE ID + SUSCEPT LRH AFBUVB AFB CULTURE, BLOOD 87116 87015 Container:UVMC Blood Culture/Fungal Isolater Tube (1.5-10mL) Temperature:Ambient LRH AFBUV AFB CULTURE, RESPIRATORY and FLUIDS 87116 87015 Temperature:Refrigerated LRH AFBUVU AFB CULTURE, URINE 87116 87015 Container:STERILE CONTAINER Temperature:Refrigerated LRH AFSM AFB SMEAR ONLY 87206 Container:STERILE CONTAINER LRH AFFIRM AFFIRM VPIII 87660 87510 87480 Container:AFFIRM VPIII transport system Temperature:Ambient or Refrigerated LRH ALB ALBUMIN 82040 Container:Light Green (PST) tube; Green-top (heparin) tube, Serum separator-tube, or Red-Top Tube Temperature:Ambient, Refrigerated, or Frozen LRH ALBBF ALBUMIN, BODY FLUID LRH ALC ALCOHOL 80307 Container:Light Green (PST) tube; Green-top (heparin) tube, Serum separator-tube, or Red-Top Tube Temperature:Ambient, Refrigerated, or Frozen LRH ALDOL ALDOLASE Page 1 of 254 LAB CODE TEST NAME CPT4 CODE LRH ALDOS ALDOSTERONE LRH UALD ALDOSTERONE, URINE 24 HR LRH ALDOSRR ALDOSTERONE/RENIN RATIO LRH ALKPHBS ALKALINE PHOSPHATASE BONE SPECIFIC LRH ALKPHI ALKALINE PHOSPHATASE ISOENZYME LRH ALKP ALKALINE PHOSPHATASE, TOTAL 84075 Container:Light Green (PST) tube; Green-top (heparin) tube, Serum separator-tube, or Red-Top Tube Temperature:Ambient, Refrigerated, or Frozen LRH RSTACAC ALLERGEN - ACACIA GUM IgG LRH RSTACTH ALLERGEN - ACTH IGE LRH RSTASG ALLERGEN - ALDER, SMOOTH IGG LRH RASTALM ALLERGEN - ALMOND IGE LRH RSTALMG ALLERGEN - ALMOND IGG LRH RSTALPA ALLERGEN - ALPHA-AMYLASE IGE LRH RASTALT ALLERGEN - ALTERNARIA TENUIS IGE LRH RSTATG ALLERGEN - ALTERNARIA TENUIS IgG LRH RSTAMPE ALLERGEN - AMPICILLIN, IgE LRH RSTANCH ALLERGEN - ANCHOVY IGE LRH RSTANIS ALLERGEN - ANISEED IGE LRH RASTAPP ALLERGEN - APPLE IGE LRH RSTAPLG ALLERGEN - APPLE IGG LRH RSTAPRI ALLERGEN - APRICOT IGE LRH RSTACOT ALLERGEN - APRICOT IGG LRH RSTAW ALLERGEN - ASH, WHITE IGE LRH RSTAWG ALLERGEN - ASH, WHITE IGG LRH RSTASPA ALLERGEN - ASPARAGUS IGE LRH RSTASPR ALLERGEN - ASPARAGUS IGG LRH RASTASP ALLERGEN - ASPERGILLUS FUMIGATUS IGE LRH RSTASFG ALLERGEN - ASPERGILLUS FUMIGATUS IgG LRH RSTASNG ALLERGEN - ASPERGILLUS NIGER IGG LRH RSTPULL ALLERGEN - AUREOBASIDI PULLULANS IGE LRH RSTAPG ALLERGEN - AUREOBASIDI PULLULANS IGG LRH RSTAVAC ALLERGEN - AVOCADO IGE LRH RSTAVAG ALLERGEN - AVOCADO IGG LRH RSTBAHG ALLERGEN - BAHIA GRASS IgG LRH RSTBKYG ALLERGEN - BAKERS YEAST IGG LRH RSTBANE ALLERGEN - BANANA IGE LRH RSTBANG ALLERGEN - BANANA IGG LRH RSTBARG ALLERGEN - BARLEY IGG Page 2 of 254 LAB CODE TEST NAME CPT4 CODE LRH RASTBAR ALLERGEN - BARLEY, WHOLE GRAIN IgE LRH RSTBASL ALLERGEN - BASIL IGE LRH RSTBASG ALLERGEN - BASIL IgG LRH RSTBAYG ALLERGEN - BAYLEAF (LAUREL) IgG LRH RSTBAYL ALLERGEN - BAYLEAF IGE LRH RSTGBE ALLERGEN - BEAN, GREEN IGE LRH RSTGBG ALLERGEN - BEAN, GREEN IGG LRH RSTBNK ALLERGEN - BEAN, KIDNEY IGE LRH RSTBKG ALLERGEN - BEAN, KIDNEY IGG LRH RSTBNL ALLERGEN - BEAN, LIMA IGE LRH RSTLBG ALLERGEN - BEAN, LIMA IGG LRH RSTWHBN ALLERGEN - BEAN, WHITE IGE LRH RSTWBNG ALLERGEN - BEAN, WHITE IGG LRH RSTBCH ALLERGEN - BEECH, AMERICAN IGE LRH RSTBEFE ALLERGEN - BEEF IGE LRH RSTBFG ALLERGEN - BEEF IGG LRH RSTBER ALLERGEN - BERMUDA GRASS IGE LRH RSTBNGG ALLERGEN - BING CHERRY IGG LRH RSTBIP ALLERGEN - BIPOLARIS IGE LRH RSTBBER ALLERGEN - BLACKBERRY IGE LRH RSTBBG ALLERGEN - BLACKBERRY IGG LRH RSTBCHG ALLERGEN - BLUE CHEESE MOLD IGG LRH RSTBCHS ALLERGEN - BLUE CHEESE MOLD, IGE LRH RSTBLUE ALLERGEN - BLUEBERRY IGE LRH RSTBLUG ALLERGEN - BLUEBERRY IGG LRH RSTBGRS ALLERGEN - BLUEGRASS, KENTUCKY IGE LRH RSTBCG ALLERGEN - BOTRYTIS CINEREA IgG LRH RSTBRAZ ALLERGEN - BRAZIL NUT IGE LRH RSTBRZG ALLERGEN - BRAZIL NUT IGG LRH RSTBROC ALLERGEN - BROCCOLI IGE LRH RSTBRCG ALLERGEN - BROCCOLI IGG LRH RSTBRUS ALLERGEN - BRUSSEL SPROUTS IGE LRH RSTBSPG ALLERGEN - BRUSSEL SPROUTS IGG LRH RSTBWHT ALLERGEN - BUCKWHEAT IgE LRH RSTBWG ALLERGEN - BUCKWHEAT IGG LRH RSTBUDD ALLERGEN - BUDGERIGAR DROPPINGS IGE LRH RSTBUDG ALLERGEN - BUDGERIGAR FEATHERS IGE LRH RSTBUMB ALLERGEN - BUMBLEBEE IGE Page 3 of 254 LAB CODE TEST NAME CPT4 CODE LRH RSTBUMG ALLERGEN - BUMBLEBEE IgG LRH RSTCBG ALLERGEN - CABBAGE IGE LRH RSTCBGG ALLERGEN - CABBAGE IGG LRH RASTCAN ALLERGEN - CANARY FEATHERS IGE LRH RSTCALB ALLERGEN - CANDIDA ALBICANS IGE LRH RSTCAG ALLERGEN - CANDIDA ALBICANS IgG LRH RSTCARA ALLERGEN - CARAGEENAN GUM IGE LRH RSTCARB ALLERGEN - CAROB BEAN FLOUR IGE LRH RASTCAR ALLERGEN - CARROT IGE LRH RSTCARG ALLERGEN - CARROT IGG LRH RASTCAS ALLERGEN - CASEIN IGE LRH RSTCASG ALLERGEN - CASEIN IGG LRH RSTCASE ALLERGEN - CASHEW NUT IGE LRH RSTCASH ALLERGEN - CASHEW NUT IGG LRH RSTCATE ALLERGEN - CAT EPITHELIUM/DANDER IGE LRH RSTCATG ALLERGEN - CAT HAIR/DANDER IGG LRH RSTCFE ALLERGEN - CATFISH IGE LRH RSTCFG ALLERGEN - CATFISH IgG LRH RSTCLFW ALLERGEN - CAULIFLOWER IGE LRH RSTCFRG ALLERGEN - CAULIFLOWER IGG LRH RASTCED ALLERGEN - CEDAR, MOUNTAIN IGE LRH RSTCMG ALLERGEN - CEDAR, MOUNTAIN IGG LRH RSTCED ALLERGEN - CEDAR, RED IGE LRH RSTCELR ALLERGEN - CELERY IGE LRH RSTCELG ALLERGEN - CELERY IGG LRH RSTCEPH ALLERGEN - CEPHALOSPORIN DRUG IGE LRH RSTCGG ALLERGEN - CHAETOMIUM GLOBOSUM IGG LRH RSTCHES ALLERGEN - CHEESE, AMERICAN IGE LRH RASTCHS ALLERGEN - CHEESE, CHEDDAR IGE LRH RSTCHDG ALLERGEN - CHEESE, CHEDDAR IGG LRH RSTCHER ALLERGEN - CHERRY IGE LRH RSTCHKP ALLERGEN - CHICK PEA IGE LRH RSTCKPG ALLERGEN - CHICK PEA IgG LRH RSTCHF ALLERGEN - CHICKEN FEATHERS IGE LRH RASTCHK ALLERGEN - CHICKEN IGE LRH RSTCHKG ALLERGEN - CHICKEN IGG LRH RSTCHOG ALLERGEN - CHOCOLATE IGG LRH RSTCHC ALLERGEN - CHOCOLATE/COCOA IGE Page 4 of 254 LAB CODE TEST NAME CPT4 CODE LRH RSTCINN ALLERGEN - CINNAMON IGE LRH RSTCING ALLERGEN - CINNAMON IGG LRH RSTCLDE ALLERGEN - CLADOSPORIUM HERBARUM IGE LRH RSTCHG ALLERGEN - CLADOSPORIUM HERBARUM IGG LRH RSTCLAM ALLERGEN - CLAM IGE LRH RSTCLMG ALLERGEN - CLAM IGG LRH RSTCLOV ALLERGEN - CLOVES IGE LRH RSTCLVG ALLERGEN - CLOVES IgG LRH RSTCBUR ALLERGEN - COCKLEBUR IGE LRH RSTCRE ALLERGEN - COCKROACH, AMERICAN IGE LRH RSTGCR ALLERGEN - COCKROACH, GERMAN IGE LRH RSTCNUT ALLERGEN - COCONUT IGE LRH RSTCOCG ALLERGEN - COCONUT IGG LRH RASTCOD ALLERGEN - CODFISH IGE LRH RSTCODG ALLERGEN - CODFISH IGG LRH RSTCOFF ALLERGEN - COFFEE IGE LRH RSTCOFG ALLERGEN - COFFEE IGG LRH RSTCORN ALLERGEN - CORN IGE LRH RSTCRNG ALLERGEN - CORN IGG LRH RSTCLU ALLERGEN - COTTON LINTERS (UNTREATED) IGE LRH RSTCSED ALLERGEN - COTTONSEED IGE LRH RSTCTNG ALLERGEN - COTTONSEED IGG LRH RSTCOTT ALLERGEN - COTTONWOOD TREE IGE LRH RSTCWTG ALLERGEN - COTTONWOOD TREE IGG LRH RSTCOWE ALLERGEN - COW EPITHELIUM IGE LRH RSTCRAB ALLERGEN - CRAB IGE LRH RSTCRBG ALLERGEN - CRAB IGG LRH RSTCBRY ALLERGEN - CRANBERRY IGE LRH RSTCBRG ALLERGEN - CRANBERRY IGG LRH RSTCFSH ALLERGEN - CRAYFISH IGE LRH RSTCRFG ALLERGEN - CRAYFISH IgG LRH RASTCUC ALLERGEN - CUCUMBER IGE LRH RSTCUCG ALLERGEN - CUCUMBER IGG LRH RSTCUMN ALLERGEN - CUMIN IGE LRH RSTCUMG ALLERGEN - CUMIN IgG LRH RSTCURR ALLERGEN - CURRY IGE LRH RSTCURG ALLERGEN - CURRY IgG LRH RSTCLG ALLERGEN - CURVULARIA LUNATA IGG Page 5 of 254 LAB CODE TEST NAME CPT4 CODE LRH RASTCB ALLERGEN - CYPRESS, BALD IGE LRH RASTDF ALLERGEN - D. FARINAE IGE LRH RASTDPE ALLERGEN - D. PTERONYSSINUS IGE LRH RSTDATE ALLERGEN - DATE IGE LRH RSTDATG ALLERGEN - DATE IGG LRH RSTDILL ALLERGEN - DILL IGE LRH RSTDILG ALLERGEN - DILL IgG LRH RSTDOCW ALLERGEN - DOCKWEED, YELLOW IGE LRH RASTDOG ALLERGEN - DOG DANDER IGE LRH RSTDUCK ALLERGEN - DUCK FEATHERS IGE LRH RSTEGYW ALLERGEN - EGG (YOLK & WHITE) IGE LRH RSTEGWE ALLERGEN - EGG WHITE IGE LRH RSTEGWG ALLERGEN - EGG WHITE IGG LRH RASTEGY ALLERGEN - EGG YOLK IGE LRH RSTEGYG ALLERGEN - EGG YOLK IGG LRH RSTEWG ALLERGEN - EGG, WHOLE IGG LRH RSTEWWG ALLERGEN - EGG, WHOLE IgG4 LRH RSTEGGP ALLERGEN - EGGPLANT IGE LRH RSTEGPG ALLERGEN - EGGPLANT IgG LRH RSTEA ALLERGEN - ELM, AMERICAN IGE LRH RSTEAG ALLERGEN - ELM, AMERICAN IGG LRH RSTENPL ALLERGEN - ENGLISH PLANTAIN IGE LRH RSTEPIC ALLERGEN - EPICOCCUM PURPUR IGE LRH RSTEPG ALLERGEN - EPICOCCUM PURPUR IGG LRH RSTETOX ALLERGEN - ETHYLENE OXIDE IGE LRH RSTFESC ALLERGEN - FESCUE, MEADOW IGE LRH RSTFINC ALLERGEN - FINCH FEATHERS IGE LRH RASTFD ALLERGEN - FIR, DOUGLAS IGE LRH RSTFLXG ALLERGEN - FLAXSEED IGG LRH RSTFLOU ALLERGEN - FLOUNDER IGE LRH RSTFLG ALLERGEN - FLOUNDER IGG LRH FOOD19R ALLERGEN - FOOD IGE (19) PANEL w REFLEX LRH FOOD20 ALLERGEN - FOOD IGE (20) PANEL LRH 22FOOD ALLERGEN - FOOD IGE (22) PANEL LRH RTFOOD ALLERGEN - FOOD IGE (6) PANEL LRH FOOD20G ALLERGEN - FOOD IGG (20) PANEL LRH RSTFORM ALLERGEN - FORMALDEHYDE IGE LRH RSTFUSO ALLERGEN - FUSARIUM PROLIFERATUM IGE Page 6 of 254 LAB CODE TEST NAME CPT4 CODE LRH
Recommended publications
  • Labcorp and the Clinical Lab Testing Industry

    Labcorp and the Clinical Lab Testing Industry

    UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF NORTH CAROLINA GREENSBORO DIVISION ) SHERYL ANDERSON, MARY CARTER, ) TENA DAVIDSON, ROBERT ) HUFFSTUTLER, RAMZI KHAZEN, ) CASE NO. 1:17-cv-193 CHAIM MARCUS, LILY MARTYN, ) JONAH MCCAY, HOLDEN SHERIFF, ) VICTORIA SMITH, MICHELLE ) JURY TRIAL REQUESTED SULLIVAN, SHONTELLE THOMAS, ) JOSEPH WATSON, and MICHAEL ) WILSON individually and on behalf of all ) others similarly situated, ) ) Plaintiffs, ) ) vs. ) ) LABORATORY CORPORATION OF ) AMERICA HOLDINGS, ) ) Defendant. ) ) AMENDED CLASS ACTION COMPLAINT Case 1:17-cv-00193-TDS-JLW Document 42 Filed 08/10/18 Page 1 of 142 TABLE OF CONTENTS INTRODUCTION ............................................................................................................... 1 JURISDICTION AND VENUE .......................................................................................... 7 PARTIES ............................................................................................................................. 7 A. Plaintiffs .............................................................................................................. 7 B. Defendant ............................................................................................................ 9 FACTUAL ALLEGATIONS .............................................................................................. 9 A. LabCorp and the Clinical Lab Testing Industry ................................................. 9 B. LabCorp’s Business Model ..............................................................................
  • Interplay Between Gating and Block of Ligand-Gated Ion Channels

    Interplay Between Gating and Block of Ligand-Gated Ion Channels

    brain sciences Review Interplay between Gating and Block of Ligand-Gated Ion Channels Matthew B. Phillips 1,2, Aparna Nigam 1 and Jon W. Johnson 1,2,* 1 Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA; [email protected] (M.B.P.); [email protected] (A.N.) 2 Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA * Correspondence: [email protected]; Tel.: +1-(412)-624-4295 Received: 27 October 2020; Accepted: 26 November 2020; Published: 1 December 2020 Abstract: Drugs that inhibit ion channel function by binding in the channel and preventing current flow, known as channel blockers, can be used as powerful tools for analysis of channel properties. Channel blockers are used to probe both the sophisticated structure and basic biophysical properties of ion channels. Gating, the mechanism that controls the opening and closing of ion channels, can be profoundly influenced by channel blocking drugs. Channel block and gating are reciprocally connected; gating controls access of channel blockers to their binding sites, and channel-blocking drugs can have profound and diverse effects on the rates of gating transitions and on the stability of channel open and closed states. This review synthesizes knowledge of the inherent intertwining of block and gating of excitatory ligand-gated ion channels, with a focus on the utility of channel blockers as analytic probes of ionotropic glutamate receptor channel function. Keywords: ligand-gated ion channel; channel block; channel gating; nicotinic acetylcholine receptor; ionotropic glutamate receptor; AMPA receptor; kainate receptor; NMDA receptor 1. Introduction Neuronal information processing depends on the distribution and properties of the ion channels found in neuronal membranes.
  • (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al

    (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al

    USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb.
  • Report of the 2014 ELA Families / Scientists Meeting

    Report of the 2014 ELA Families / Scientists Meeting

    Report 2014 ELA Families - Scientists meeting April 5 & 6, 2014 Paris, France 2014 ELA FAMILIES – SCIENTISTS MEETING April 5‐6, 2014 Paris, France The 2014 ELA Families/Scientists meeting gathered 360 participants in Paris, among them 27 international scientists with expertise in leukodystrophies and myelin diseases. During the 8 diseases’ workshops and the plenary session organized, scientists presented the results of their research work in lay language and answered questions from patients and their families. This special report compiles the information presented during the scientific workshops. Summary Diseases’ workshops . Workshop on ALD/AMN . Workshop on Refsum disease . Workshop on MLD . Workshop on Krabbe disease . Workshop on CACH/VWM syndrome, Alexander disease, MLC and Canavan disease . Workshop on PMD and other hypomyelinating leukodystrophies . Workshop on undetermined leukodystrophies . Workshop on Aicardi‐Goutières syndrome ‐‐‐ *ALD: AdrenoLeukoDystrophy; AMN: AdrenoMyeloNeuropathy; MLD: Metachromatic Leukodystrophy; CACH/VWM: Childhood Ataxia with Central nervous system Hypomyelination / Vanishing White Matter; MLC: Megalencephalic Leukoencephalopathy with subcortical Cysts; PMD: Pelizaeus‐Merzbacher Disease 2014 ELA Families/Scientists meeting ‐ Report Page 1 DISEASES’ WORKSHOPS WORKSHOP ON ALD/AMN CLINICAL TRIALS EVALUATING THE IMPORTANCE OF STRENGTH ON FUNCTION IN AMN Kathleen Zackowski Ph.D., OTR, MSCS Kennedy Krieger Institute, Baltimore, MD, USA X‐linked adrenoleukodystrophy, a progressive neurodegenerative disease, is caused by a defect in the ABCD1 gene. The disease has multiple subtypes, but the most common form is adrenomyeloneuropathy (AMN). Our previous studies identified the symptoms of the disease in men as slowly progressive spasticity, weakness and sensory dysfunction. The worsening of these symptoms results in the progressive difficulty of walking and of balance problems.
  • Pediatric Multiple Sclerosis

    Pediatric Multiple Sclerosis

    148 Pediatric Multiple Sclerosis Ji Y. Lee, MD, PhD1 Tanuja Chitnis, MD1 1 Department of Pediatric Neurology, Massachusetts General Hospital, Address for correspondence Tanuja Chitnis, MD, Department of Harvard Medical School, Boston, Massachusetts Pediatric Neurology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, ACC708, Boston, MA 02114 Semin Neurol 2016;36:148–153. (e-mail: [email protected]). Abstract Pediatric multiple sclerosis (MS) is a chronic inflammatory neurologic disease that is challenging to diagnose and treat. Although there are many clinical parallels between pediatric-onset MS and adult-onset MS, there is also accumulating evidence of distin- guishing clinical features that may, in part, arise from development-specific, neuro- immune processes governing MS pathogenesis in children. Here the authors describe the clinical features, diagnosis, and treatment of pediatric MS, with a particular focus on describing clinical features and highlighting new developments that promise a better understanding of pediatric MS pathogenesis. An important task that lies ahead for pediatric neurologists is better understanding the early gene–environment interaction Keywords that precipitates the first demyelinating event in pediatric MS. This area is of particular ► multiple sclerosis importance for understanding the MS etiology and the natural history of pediatric MS. ► children Such understanding should in turn inform new developments in diagnostic tools, long- ► demyelination term therapies, and much-needed biomarkers.
  • Our Five Pillars Of

    Our Five Pillars Of

    L aboratory Corporation of America 2011 Annual Report Our Five Pillars of ® Laboratory Corporation of America Holdings Success 358 South Main Street Burlington, NC 27215 336-584-5171 www.labcorp.com 2011 ANNUAL REPORT 120097_L01_CVR.indd 1 3/12/12 2:07 PM Laboratory Corporation OF America About LabCorp® Shareholder and Company Information Laboratory Corporation of America® Holdings, an S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $5.5 billion in 2011, over 31,000 employees worldwide, and more than 220,000 clients, LabCorp offers more than 4,000 tests Corporate Headquarters Transfer Agent Safe Harbor 358 South Main Street American Stock Transfer & Trust Company Forward-looking statements in this annual report ranging from routine blood analyses to reproductive genetics to companion diagnostics. Burlington, NC 27215 Shareholder Services are subject to change based on various important 336-584-5171 6201 Fifteenth Avenue factors, including without limitation, competitive LabCorp furthers its scientific expertise and innovative clinical testing technology Brooklyn, NY 11219 actions in the marketplace and adverse actions through its specialized labs and the LabCorp Specialty Testing Group: The Center for Information Sources 800-937-5449 of governmental and other third-party payers. Information about LabCorp is available from www.amstock.com Actual results could differ materially from those Molecular Biology and Pathology, National
  • A Time-Updated, Parsimonious Model to Predict AKI in Hospitalized Children

    A Time-Updated, Parsimonious Model to Predict AKI in Hospitalized Children

    CLINICAL RESEARCH www.jasn.org A Time-Updated, Parsimonious Model to Predict AKI in Hospitalized Children Ibrahim Sandokji ,1,2 Yu Yamamoto ,2 Aditya Biswas,2 Tanima Arora ,2 Ugochukwu Ugwuowo,2 Michael Simonov,2 Ishan Saran,2 Melissa Martin ,2 Jeffrey M. Testani,3 Sherry Mansour,2 Dennis G. Moledina ,2 Jason H. Greenberg ,1,2 and F. Perry Wilson 2 1Department of Pediatrics, Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut 2Clinical and Translational Research Accelerator, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 3Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut ABSTRACT Background Timely prediction of AKI in children can allow for targeted interventions, but the wealth of data in the electronic health record poses unique modeling challenges. Methods We retrospectively reviewed the electronic medical records of all children younger than 18 years old who had at least two creatinine values measured during a hospital admission from January 2014 through January 2018. We divided the study population into derivation, and internal and external valida- tion cohorts, and used five feature selection techniques to select 10 of 720 potentially predictive variables from the electronic health records. Model performance was assessed by the area under the receiver operating characteristic curve in the validation cohorts. The primary outcome was development of AKI (per the Kidney Disease Improving Global Outcomes creatinine definition) within a moving 48-hour win- dow. Secondary outcomes included severe AKI (stage 2 or 3), inpatient mortality, and length of stay. Results Among 8473 encounters studied, AKI occurred in 516 (10.2%), 207 (9%), and 27 (2.5%) encounters in the derivation, and internal and external validation cohorts, respectively.

  • D40. Cerebrospinal Fluid.Pdf

    CEREBROSPINAL FLUID D40 (1) Cerebrospinal Fluid (CSF) Last updated: June 3, 2019 PHYSIOLOGY ............................................................................................................................................ 1 CSF PRODUCTION .................................................................................................................................. 1 CSF REABSORPTION ............................................................................................................................... 1 PARAMETERS ........................................................................................................................................... 2 NORMAL ................................................................................................................................................ 2 OPENING PRESSURE ................................................................................................................................ 3 COLOR ................................................................................................................................................... 3 BLOODY CSF ......................................................................................................................................... 3 VISCOSITY & TURBIDITY ....................................................................................................................... 4 CELLS ...................................................................................................................................................
  • Canavan Disease: a Neurometabolic Disease Caused by Aspartoacylase Deficiency

    Canavan Disease: a Neurometabolic Disease Caused by Aspartoacylase Deficiency

    Journal of Pediatric Sciences SPECIAL ISSUE Current opinion in pediatric metabolic disease Editor: Ertan MAYATEPEK Canavan Disease: A Neurometabolic Disease Caused By Aspartoacylase Deficiency Ute Lienhard and Jörn Oliver Sass Journal of Pediatric Sciences 2011;3(1):e71 How to cite this article: Lienhard U, Sass JO. Canavan disease: a neurometabolic disease caused by aspartoacylase deficiency. Journal of Pediatric Sciences. 2011;3(1):e71 JPS 2 REVIEW ARTICLE Canavan Disease: A Neurometabolic Disease Caused By Aspartoacylase Deficiency Ute Lienhard and Jörn Oliver Sass Abstract: Canavan disease is a genetic neurodegenerative disorder caused by mutations in the ASPA gene encoding aspartoacylase, also known as aminoacylase 2. Important clinical features comprise progressive psychomotor delay, macrocephaly, muscular hypotonia as well as spasticity and visual impairment. Cerebral imaging usually reveals leukodystrophy. While it is often expected that patients with Canavan disease will die in childhood, there is increasing evidence for heterogeneity of the clinical phenotype. Aspartoacylase catalyzes the hydrolysis of N- acetylaspartate (NAA) to aspartate and acetate. Its deficiency leads to accumulation of NAA in the brain, blood, cerebrospinal fluid and in the urine of the patients. High levels of NAA in urine are detectable via the assessment of organic acids by gas chromatography - mass spectrometry. Confirmation is available by enzyme activity tests and mutation analyses. Up to now, treatment of patients with Canavan disease is only symptomatic. Although it is a panethnic disorder, information on affected individuals in populations of other than Ashkenazi Jewish origin is rather limited. Ongoing research aims at a better understanding of Canavan disease (and of related inborn errors of metabolism such as aminoacylase 1 deficiency).
  • Membership | July 2021

    Membership | July 2021

    Membership | July 2021 CLINICAL LABORATORY INDUSTRY/TRADE CureDuchenne Duke Center for Research Vanderbilt University TESTING SERVICES ASSOCIATIONS Emily’s Entourage on Personalized Health Medical Center Dasman Diabetes Institute American Clinical EveryLife Foundation for Care West Cancer Center Invitae Laboratory Association Rare Disease Essentia Institute of Rural Laboratory Corporation of BIO (Biotechnology Fight Colorectal Cancer Health RESEARCH TOOL America (LabCorp) Innovation Organization) Friends of Cancer European Infrastructure for COMPANIES Quest Diagnostics Biocom California Research Translational Medicine Octave Biosciences PhRMA GI Cancers Alliance Harvard Business School DIAGNOSTIC Global Liver Institute Hospital Albert Einstein STRATEGIC PARTNERS COMPANIES IT/INFORMATICS GO2 Foundation for Lung HudsonAlpha Institute for Accenture Admera Health COMPANIES Cancer Biotechnology Arnold & Porter Agendia NV 2bPrecise HealthyWomen iCAN – Digital Precision Artisan Healthcare Agilent Technologies Assurance Health Data International Cancer Cancer Medicine at Consulting Alacris Theranostics Change Healthcare Advocacy Network University of Helsinki Bioscience Valuation BSV GmbH Concert Genetics KRAS Kickers Instituto de Salud Carlos III GmbH Almac Diagnostics DNAnexus LUNGevity Foundation Intermountain Healthcare Blue Latitude Health Asuragen Flatiron Health Multiple Myeloma Johns Hopkins Boston Healthcare Caprion Proteomics GNS Healthcare Research Foundation Individualized Health Associates Caris Life Sciences M2Gen National Alliance
  • Please See the Linked

    Please See the Linked

    Stocks to watch On the prowl for big gain Six investment pros shared their favorite North Carolina stocks for 2017 and companies to avoid, continuing a longBUSINESS NORTH CAROLINA tradition. With the ranks of publicly held companies dwindling, this year’s forecasts include some companies based outside the state but with large Tar Heel operations. The picks range from international giants to speculative small-cap stocks. RULES OF THE GAME Pickers were asked to select their three favorite North Carolina stocks. Graphs are based on each stock’s performance between Jan. 1, 2016 and Dec. 13, 2016. Expected growth rates and percentage of industry 54 Business north analysts with Carolina “buy ratings” is based on data from Thomson/First Call. Ann Benjamin Zuraw Patrick Rush President, Zuraw Financial Advisors LLC, Chief executive officer, Triad Financial Advisors, Greensboro Greensboro (2%) 2% LOWE’S SYNGENTA COS. (LOW) AG (SYT) JAN ’16 ............................DEC ’16 JAN ’16 ............................DEC ’16 MARKET CAP: $63.4 BILLION MARKET CAP: $38.1 BILLION P/E RATIO: 27 EXPECTED FIVE-YEAR EPS GROWTH: 16% P/E RATIO: 31 EXPECTED FIVE-YEAR EPS GROWTH: 8% Lowe’s is the second-largest home-improvement retailer in the world A leading Swiss agricultural company with significant operations with 2,300 stores. Recent earnings were disappointing, particularly in in North Carolina, it is being acquired by ChemChina at about same-store sales growth compared with Home Depot, leaving a valu- $93 per share. Regulators are considering the buyout and have ation discount. More household formation and bank lending should delayed their decision, sparking speculation that the deal will be prompt more home-improvement spending.
  • The CEO Action for Diversity & Inclusion™ Aims to Rally The

    The CEO Action for Diversity & Inclusion™ Aims to Rally The

    The CEO Action for Diversity & Inclusion™ aims to rally the business community to advance diversity & inclusion within the workplace by working collectively across organizations and sectors. It outlines a specific set of actions the undersigned companies will take to cultivate a trusting environment where all ideas are welcomed and employees feel comfortable and empowered to discuss diversity & inclusion. All the signatories serve as leaders of their companies and have committed to implementing the following pledge within their workplaces. Where companies have already implemented one or several of the commitments, the undersigned commit to support other companies in doing the same. The persistent inequities across our country underscore our urgent, national need to address and alleviate racial, ethnic and other tensions and to promote diversity within our communities. As leaders of some of America’s largest corporations, we manage thousands of employees and play a critical role in ensuring that inclusion is core to our workplace culture and that our businesses are representative of the communities we serve. Moreover, we know that diversity is good for the economy; it improves corporate performance, drives growth and enhances employee engagement. Simply put, organizations with diverse teams perform better. We recognize that diversity & inclusion are multifaceted issues and that we need to tackle these subjects holistically to better engage and support all underrepresented groups within business. To do this, we believe we also need to address honestly and head-on the concerns and needs of our diverse employees and increase equity for all, including Blacks, Latinos, Asians, Native Americans, LGBTQ, disabled, veterans and women.